ELVN
Enliven Therapeutics, Inc.
$50.87
-0.22 (-0.43%)
At close · Jul 13
Market Cap
$3.10B
Shares
60,904,946
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-06-12 | 2026-06-11 | |
| 8-K | 2026-06-11 | — | |
| 8-K | 2026-06-10 | 2026-06-09 | |
| 8-K | 2026-05-07 | — | |
| 10-Q | 2026-05-07 | 2026-03-31 | |
| DEF 14A | 2026-04-27 | 2026-06-09 | |
| 10-K | 2026-03-03 | 2025-12-31 | |
| 8-K | 2026-03-03 | — | |
| 8-K | 2026-01-07 | 2026-01-06 | |
| 8-K | 2025-12-11 | 2025-12-09 | |
| 8-K/A | 2025-11-13 | 2025-11-12 | |
| 8-K | 2025-11-12 | — | |
| 10-Q | 2025-11-12 | 2025-09-30 | |
| 10-Q | 2025-08-13 | 2025-06-30 | |
| 8-K | 2025-08-13 | — | |
| 8-K | 2025-06-25 | 2025-06-24 | |
| 8-K | 2025-06-16 | 2025-06-13 | |
| 8-K | 2025-06-13 | — | |
| 10-Q | 2025-05-14 | 2025-03-31 | |
| 8-K | 2025-05-14 | — | |
| DEF 14A | 2025-04-28 | 2025-06-24 | |
| 8-K | 2025-03-13 | — | |
| 10-K | 2025-03-13 | 2024-12-31 | |
| 8-K | 2024-11-13 | — | |
| 10-Q | 2024-11-13 | 2024-09-30 | |
| 8-K | 2024-08-13 | — | |
| 10-Q | 2024-08-13 | 2024-06-30 | |
| 8-K | 2024-06-18 | — | |
| 8-K/A | 2024-05-29 | 2024-04-08 | |
| 8-K | 2024-05-14 | — | |
| 10-Q | 2024-05-14 | 2024-03-31 | |
| DEF 14A | 2024-04-26 | 2024-06-18 | |
| 8-K | 2024-04-11 | — | |
| 8-K | 2024-04-09 | 2024-04-08 | |
| 8-K | 2024-03-19 | — | |
| 8-K | 2024-03-14 | — | |
| 10-K | 2024-03-14 | 2023-12-31 | |
| 8-K | 2023-11-09 | — | |
| 10-Q | 2023-11-09 | 2023-09-30 | |
| 8-K | 2023-08-10 | — | |
| 10-Q | 2023-08-10 | 2023-06-30 | |
| 8-K | 2023-06-26 | 2023-06-23 | |
| 8-K | 2023-06-23 | — | |
| 8-K | 2023-05-11 | — | |
| 10-Q | 2023-05-11 | 2023-03-31 | |
| DEF 14A | 2023-04-28 | 2023-06-23 | |
| 8-K/A | 2023-03-21 | 2023-02-23 | |
| 8-K | 2023-03-01 | 2023-02-23 | |
| 8-K | 2023-02-22 | — |
Showing 1–50 of 90 filings
Key facts
CIK
1672619
CUSIP
29337E102
13F (30d)
11 filings
10 filers
Visit website
Investor relations